Cellular Therapy for Fanconi Anemia: The Past, Present, and Future

被引:16
|
作者
MacMillan, Margaret L. [1 ]
Hughes, Mark R. [2 ]
Agarwal, Suneet [3 ,4 ,5 ,6 ,7 ]
Daley, George Q. [3 ,4 ,5 ,6 ,7 ]
机构
[1] Univ Minnesota, Dept Pediat, Div Pediat Hematol Oncol & Blood & Marrow Transpl, Blood & Marrow Transplant Program, Minneapolis, MN 55455 USA
[2] Appl Genom Technol Ctr Michigan, Genesis Genet Inst, Detroit, MI USA
[3] Childrens Hosp Boston, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Stem Cell Transplantat Program,Div Pediat Hematol, Boston, MA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
[7] Harvard Stem Cell Inst, Boston, MA USA
关键词
BONE-MARROW-TRANSPLANTATION; PLURIPOTENT STEM-CELLS; APLASTIC-ANEMIA; DONORS; CYCLOPHOSPHAMIDE; IRRADIATION; DISEASE; BLOOD; ENGRAFTMENT; GENERATION;
D O I
10.1016/j.bbmt.2010.11.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Allogeneic hematopoietic cell transplantation (HCT) remains the only proven curative therapy for the hematologic manifestation of Fanconi anemia (FA). Over the past 2 decades, major advances have been made such that transplant outcomes have markedly improved. With the development of in vitro fertilization and preimplantation genetic diagnosis, HLA-matched sibling donor umbilical blood transplantation may be an option for more patients with FA. Recently, the use of pluripotent stem cells has been explored as a novel approach to model the hematopoietic developmental defects in FA, and to provide a potential source of autologous stem cells that can be genetically manipulated and used to generate corrected hematopoietic progenitors. Biol Blood Marrow Transplant 17: S109-S114 (2011) (C) 2011 American Society for Blood and Marrow Transplantation
引用
收藏
页码:S109 / S114
页数:6
相关论文
共 50 条
  • [1] Cell Therapy: Past, Present, and Future
    Hamon, Morgan
    Hauser, Peter, V
    CURRENT TRANSPLANTATION REPORTS, 2019, 6 (02) : 109 - 118
  • [2] Therapeutic strategies in Sickle Cell Anemia: The past present and future
    Fernandes, Queenie
    LIFE SCIENCES, 2017, 178 : 100 - 108
  • [3] Cellular regeneration strategies for macular degeneration: past, present and future
    Chichagova, Valeria
    Hallam, Dean
    Collin, Joseph
    Zerti, Darin
    Dorgau, Birthe
    Felemban, Majed
    Lako, Majlinda
    Steel, David H.
    EYE, 2018, 32 (05) : 946 - 971
  • [4] Anti-TNF therapy: past, present and future
    Monaco, Claudia
    Nanchahal, Jagdeep
    Taylor, Peter
    Feldmann, Marc
    INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 55 - 62
  • [5] Alternative donor hematopoietic cell transplantation for Fanconi anemia
    MacMillan, Margaret L.
    DeFor, Todd E.
    Young, Jo-Anne H.
    Dusenbery, Kathryn E.
    Blazar, Bruce R.
    Slungaard, Arne
    Zierhut, Heather
    Weisdorf, Daniel J.
    Wagner, John E.
    BLOOD, 2015, 125 (24) : 3798 - 3804
  • [6] Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future
    Chen, Hui Hsuan
    Sawamoto, Kazuki
    Mason, Robert W.
    Kobayashi, Hironori
    Yamaguchi, Seiji
    Suzuki, Yasuyuki
    Orii, Kenji
    Orii, Tadao
    Tomatsu, Shunji
    JOURNAL OF HUMAN GENETICS, 2019, 64 (11) : 1153 - 1171
  • [7] Cell therapy for liver disorders: past, present and future
    Ortuno-Costela, M. Carmen
    Pinzani, Massimo
    Vallier, Ludovic
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2025, : 329 - 342
  • [8] Hodgkin's lymphoma therapy: past, present, and future
    Rathore, Bharti
    Kadin, Marshall E.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (17) : 2891 - 2906
  • [9] Stem Cell Therapy for Fanconi Anemia
    Zhang, Qing-Shuo
    STEM CELLS: BIOLOGY AND ENGINEERING, 2018, 1083 : 19 - 28
  • [10] Perspectives on gene therapy for Fanconi anemia
    Navarro, Susana
    Rio, Paula
    Bueren, Juan A.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (08): : 899 - 910